Generic Name: elvitegravir
Applies to elvitegravir: oral tablet
As well as its needed effects, elvitegravir (the active ingredient contained in Vitekta) may cause unwanted side effects that require medical attention. 
Some elvitegravir side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:


Applies to elvitegravir: oral tablet
Very common (10% or more): Increased lipase (14%), diarrhea (up to 13%)Common (1% to 10%): Abdominal pain, vomiting, nausea, increased serum amylaseUncommon (0.1% to 1%): Dyspepsia, abdominal distension, flatulence[Ref]
Increased serum amylase (greater than 2 times the upper limit of normal [2 x ULN]) has been reported in 6% of patients.If serum amylase was greater than 1.5 x ULN, lipase was also measured.  Increased lipase (grades 3 to 4) has been reported in 14% of patients.[Ref]
Increased total bilirubin (greater than 2.5 x ULN), GGT (greater than 5 x ULN), ALT (greater than 5 x ULN), and AST (greater than 5 x ULN) have been reported in 6%, 3%, 2%, and 2% of patients, respectively.[Ref]
Common (1% to 10%): Increased total bilirubin, increased ALT, increased AST[Ref]
Increased creatine kinase (at least 10 x ULN) has been reported in 6% of patients.[Ref]
Common (1% to 10%): Increased creatine kinase, back pain, arthralgia, pain in extremityFrequency not reported: Osteonecrosis[Ref]
Hematuria (greater than 75 RBC/high power field) and urine glucose (4+) have been reported in 6% and 4% of patients, respectively.[Ref]
Common (1% to 10%): Hematuria, urine glucose[Ref]
Increased total cholesterol (greater than 300 mg/dL), increased total triglycerides (greater than 750 mg/dL), and hyperglycemia (greater than 250 mg/dL) have each been reported in 5% of patients.[Ref]
Common (1% to 10%): Increased total cholesterol, increased total triglycerides, hyperglycemia[Ref]
Common (1% to 10%): HeadacheUncommon (0.1% to 1%): Dizziness, paresthesia, somnolence, dysgeusia[Ref]
Common (1% to 10%): Decreased neutrophils[Ref]
Decreased neutrophils (less than 750/mm3) has been reported in 3% of patients.[Ref]
Suicidal ideation and suicide attempt were reported in patients with history of depression or psychiatric illness.[Ref]
Common (1% to 10%): DepressionUncommon (0.1% to 1%): Suicidal ideation, suicide attempt, insomnia[Ref]
Common (1% to 10%): Rash[Ref]
Common (1% to 10%): Fatigue[Ref]
Frequency not reported: Autoimmune disorders (e.g., Graves' disease)[Ref]
1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0
2. Cerner Multum,  Inc. "Australian Product Information." O 0
3. EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."  
4. "Product Information. Vitekta (elvitegravir)." Gilead Sciences, Foster City, CA. 
It is possible that some side effects of Vitekta may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

Diarrhea


Headache
nausea


Discouragement
feeling sad or empty
heartburn
indigestion
irritability
lack of appetite
loss of interest or pleasure
rash
stomach discomfort, upset, or pain
thoughts or attempts at killing oneself
trouble concentrating
trouble sleeping
unusual tiredness or weakness
vomiting

